Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial

Publikation

Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial

Wissenschaftlicher Artikel/Review - 01.06.2004

Thürlimann Beat, Rochlitz Christoph, Aebi Stefan, Perey Lucien, Pagani Olivia, Ballabeni Pierluigi, Senn Isabella, Köberle Dieter, Hess Dagmar, Goldhirsch Aron

Thürlimann, Beat

259

Hess, Dagmar

Oberärztin mbF
Medizinische Onkologie und Hämatologie · Dept. I

Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial

Thürlimann, Beat

Hess, Dagmar

Köberle, Dieter

Senn, Isabella

Ballabeni, Pierluigi

Pagani, Olivia

Perey, Lucien

Aebi, Stefan

Rochlitz, Christoph

Goldhirsch, Aron